Mavatrep
| File:Mavatrep.svg | |
| Clinical data | |
|---|---|
| Other names | JNJ-39439335 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C25H21F3N2O |
| Molar mass | 422.451 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist.[1] It is an investigational analgesic that may be a potential treatment for pain and/or inflammation.
Phase I trials have been completed in healthy Japanese and Caucasian volunteers.[1][2]
Potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot.[2]
Pharmacokinetics
[edit | edit source]When administered orally once a day, mavatrep reached steady-state in healthy volunteers in approximately 14 days.[2] It has a relatively long half-life between 68 and 101 hours in Japanese subjects and between 82 and 130 hours in Caucasian subjects.[2]
Mavatrep is largely eliminated non-renally. Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.[2]